FDA Alerts

FDA has strengthened an existing warning of constipation associated with the use of clozapine, stating that this constipation can, uncommonly, progress to serious bowel complications, including blockage of...

The FDA has expanded the approval of a drug used for the treatment of C. difficile infection to include pediatric patients aged 6 months and older.

The FDA has expanded the approval of a drug used for the treatment of C. difficile infection to include pediatric patients aged 6 months and older.

The US Food and Drug Administration has granted approval to a treatment for thyroid eye disease. It is the first-ever drug to be approved for this indication.

The US Food and Drug Administration has approved the first and only fast-acting mealtime insulin injection that does not have a pre-dosing recommendation for use in children with diabetes.

The Food and Drug Administration (FDA) has issued an enforcement policy on the manufacturing and distribution of unauthorized flavored e-cigarette products that appeal to children.

Apixaban is approved for the prophylaxis of DVT, which may lead to PE. Now the FDA approved 2 new applications for the drug.

It is the first drug in the class of oral calcitonin gene-related peptide receptor antagonists approved for the acute treatment of migraine.

XELJANZ XR provides adult patients living with moderately to severely active UC the first and only once-daily JAK inhibitor for managing their disease.

Three applications for the first generic capsules have been granted by the US Food and Drug Administration.